• Publications
  • Influence
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
Evidence-based recommendations in response to the appointment as an independent task force by the American Thyroid Association to assist in the clinical management of patients with thyroid nodules and differentiated thyroid cancer represent, in the authors' opinion, contemporary optimal care for patients with these disorders.
Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.
Consideration of a more conservative approach for most patients with thyroid nodules that are cytologically indeterminate on fine-needle aspiration and benign according to gene-expression classifier results are suggested.
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid
Evidence-based recommendations are developed to inform clinical decision-making in the management of thyroid nodules and differentiated thyroid cancer and represent, in the authors' opinion, contemporary optimal care for patients with these disorders.
Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules.
Results indicate that molecular testing of thyroid nodules for a panel of mutations can be effectively performed in a clinical setting and enhances the accuracy of FNA cytology and is of particular value for thyroid nodule with indeterminate cytology.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
The results emphasize the importance of cell line integrity, and provide the short tandem repeat profiles for a panel of thyroid cancer cell lines that can be used as a reference for comparison of cell lines from other laboratories.
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.
This study demonstrates comparable remnant ablation rates in patients prepared for 131I remnantAblation with 3.7 GBq by either administering rhTSH or withholding thyroid hormone, and maintains a higher quality of life and received less radiation exposure to the blood.
A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.
A surveillance guideline is proposed using TSH-stimulated Tg levels for patients who have undergone total or near-total thyroidectomy and (131)I ablation for DTC and have no clinical evidence of residual tumor with a serum Tg below 1 micro g/liter during THST.
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.
Comparing the effect of administered recombinant TSH with thyroid hormone withdrawal on the results of radioiodine whole body scanning (WBS) and serum thyroglobulin (Tg) levels found recombinant human TSH administration is a safe and effective means of stimulatingRadioiodine uptake and serum Tg levels in patients undergoing evaluation for thyroid cancer persistence and recurrence.
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Indication of an influence of the residence time of radioiodine in the blood on the fractional uptake into thyroid remnant was found and a novel regimen is proposed in which therapeutic activities to be administered are determined from the individual specific blood dose.